We are monitoring the impact of COVID-19 on North America Gastroparesis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5071
Share on
Share on

North America Gastroparesis Drugs Market Research Report – Segmented By Drug Class, Disease Type, End User and Country (the United States, Canada and Rest of North America) – Industry Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 5071
Pages: 145

The size of the North America Gastroparesis Drugs market was around USD 1.90 billion in 2021. It is expected to grow at a CAGR of 4.5% to reach USD 2.37 billion by 2026. It captures 35% of the global market share.

The North American gastroparesis drugs market is majorly driven by the increasing incidence of the diabetic population across the region. Also, the rising number of surgical procedures further boosts the market growth.  In North America, the senior population is considered one of the significant growth contributors to the gastroparesis drugs market. The growing geriatric population is more vulnerable to chronic diseases such as diabetes. 

Other factors such as growing population and associated sedentary lifestyles, rapid urbanization, increasing consumption of alcohol and tobacco significantly influence market growth. In addition, the increasing research and development activities and clinical trials for Gastroparesis by the major companies in the region, primarily due to the high prevalence rate of diabetes type 1 and diabetes type 2, are expected to provide lucrative growth opportunities to market growth.  Emerging countries such as U.S. and Canada have witnessed advanced healthcare infrastructure, high healthcare spending, and government initiatives to adopt new user-friendly drugs is more likely to accelerate the regional market growth. 

Increasing investments and funding by the government and manufacturers in research and development activities to develop advanced, new approaches to the existing drug therapy are expected to uplift the market growth. Furthermore, the market participants' innovative market strategies in the region's emerging countries are expected to provide lucrative growth opportunities for market expansion. 

However, the side effects of gastroparesis drugs and complications in gastroparesis diagnosis are limiting the market growth. In addition, a time-consuming regulatory process for the approval of drugs is further hinders market growth. 

This research report on the North American gastroparesis drugs market has been segmented and sub-segmented into the following categories.

By Drug Class:

  • Prokinetic Agents 
  • Antiemetic Agents
  • Botulinum Toxin Injections    

By Disease Class:

  • Diabetic Gastroparesis       
  • Idiopathic Gastroparesis    
  • Post-surgical Gastroparesis              
  • Others      

By End User:

  • Hospitals 
  • Pharmacies            
  • Clinics      
  • E-commerce     

By Country:

  • United States
  • Canada
  • Rest of North America

Geographically, the North American market dominated the global gastroparesis drugs market, and it is anticipated to continue its dominance throughout the forecast period. The regional market growth is attributed to the high prevalence rate of Gastroparesis, growing awareness, and high healthcare expenditure. In addition, the presence of well-established healthcare infrastructure, key market players, and favorable government policies are contributing to the market growth. The highly economic countries such as the United States and Canada significantly contribute to the North American regional market expansion.

The United States accounted for the largest share of the market. It is expected to witness a predominant share owing to the Y-0-Y rising older population, increasing diabetic population, and the introduction of novel drugs.  

However, according to a review of Diabetic Gastroparesis for the Community Pharmacist, the US has diabetes and has faced complications associated with the disease. Diabetes is the most common systemic disease that causes Gastroparesis. Moreover, extensive research and development activities in pharmaceutical and biotechnology companies in the country are boosting market growth. 

On the other hand, the Canadian gastroparesis market is projected to witness a considerable share during the forecast period.

KEY MARKET PLAYERS:

Companies playing a leading role in the North American gastroparesis drugs market profiled in this report are Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma.

1.Introduction                                 

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods                          

               1.4 General Study Assumptions                 

2. Research Methodology                                          

               2.1 Introduction                             

               2.2 Research Phases                      

                              2.2.1 Secondary Research           

                              2.2.2 Primary Research 

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview                                     

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology                            

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                                            

               5.1 Drug Class                  

                              5.1.1 Introduction           

                              5.1.2 Prokinetic Agents 

                              5.1.3 Antiemetic Agents

                              5.1.4 Botulinum Toxin Injections              

                              5.1.5  Y-o-Y Growth Analysis, By Drug Class          

                              5.1.6  Market Attractiveness Analysis, By Drug Class        

                              5.1.7  Market Share Analysis, By Drug Class         

               5.2 Disease Type                            

                              5.2.1 Introduction           

                              5.2.2 Diabetic Gastroparesis       

                              5.2.3 Idiopathic Gastroparesis    

                              5.2.4 Post-surgical Gastroparesis              

                              5.2.5 Others      

                              5.2.6 Y-o-Y Growth Analysis, By Disease Type      

                              5.2.7 Market Attractiveness Analysis, By Disease Type    

                              5.2.8 Market Share Analysis, By Disease Type     

               5.3 End User                     

                              5.3.1 Introduction           

                              5.3.2 Hospitals  

                              5.3.3 Pharmacies             

                              5.3.4 Clinics       

                              5.3.5 E-commerce          

                              5.3.6 Y-o-Y Growth Analysis, By End User             

                              5.3.7 Market Attractiveness Analysis, By End User            

                              5.3.8 Market Share Analysis, By End User             

6. Geographical Analysis                                            

               6.1 Introduction                             

                              6.1.1 Regional Trends    

                              6.1.2 Impact Analysis     

                              6.1.3 Y-o-Y Growth Analysis        

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By Drug Class

                                             6.1.3.3 By Disease Type

                                             6.1.3.4 By End User

                              6.1.4  Market Attractiveness Analysis      

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By Drug Class

                                             6.1.4.3 By Disease Type

                                             6.1.4.4 By End User

                              6.1.5  Market Share Analysis       

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By Drug Class

                                             6.1.5.3 By Disease Type

                                             6.1.5.4 By End User

               6.2 United States                           

               6.3 Canada                       

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis                             

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services

                              7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis                                       

               8.1 Allergan, Plc.                            

                              8.1.1 Overview 

                              8.1.2 Product Analysis   

                              8.1.3 Financial analysis  

                              8.1.4 Recent Developments        

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View          

               8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)                      

               8.3 AstraZeneca Plc.                      

               8.4 Cadila Pharmaceuticals Ltd.                

               8.5 ETX Pharma, Inc                      

               8.6 Evoke Pharma                          

               8.7 GlaxoSmithKline Plc.                             

               8.8 Neurogastrx, Inc.                    

               8.9 Valeant Pharmaceuticals International, Inc.                 

               8.10 Theravance Biopharma                      

9. Competitive Landscape                                         

               9.1 Market share analysis                           

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures                          

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                          

               a) List of Tables                

               b) List of Figures                             

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  2. North America Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Billion)
  3. North America Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Billion)
  4. North America Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Billion)
  5. North America Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  6. North America Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  7. North America Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  8. North America Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  9. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  10. North America Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  11. North America Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  12. North America Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  13. North America Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  14. North America E-commerce Market, By Region, From 2021 to 2026 (USD Billion)
  15. United States Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  16. United States Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  17. United States Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  18. Canada Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  19. Canada Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  20. Canada Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample